证券日报网讯7月31日晚间，蓝帆医疗（002382）发布公告称，截至本次担保全部发生后，公司及子公 司的担保最高额为380，357.86万元人民币(外币担保余额均按照2025年7月31日央行公布的汇率折算)， 占公司2024年度经审计净资产的46.46%，未超过2024年度经审计净资产的50%。公司及子公司对合并报 表外单位提供的担保总余额为850万元人民币，占公司2024年度经审计净资产的0.10%。公司及子公司 无逾期对外担保、无涉及诉讼的对外担保及因担保被判决败诉而应承担损失的情形。 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-063 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于公司向银行申请授信提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、担保情况概述 蓝帆医疗股份有限公司（以下简称"公司"）于2024年12月6日召开了第六届董事 会第十六次会议、2024年12月23日召开了2024年第三次临时股东大会，审议并通过了 《关于2025年度公司及子公司申请授信及担保额度预计的议案》，公司及子公司2025 年度拟向银行等金融机构申请综合授信总额不超过人民币17.10亿元，授信品种包括但 不限于流动资金贷款、保函、银行承兑汇票、国内信用证、国内保理、融资租赁等综合 授信业务（具体业务品种以相关金融机构审批为准），具体融资金额将视公司及子公司 生产运营对资金的需求来确定。公司及子公司将根据金融机构的授信要求为上述综合 授信提供担保额度总计不超过人民币17.10亿元，其中，预计为公司及资产负债率70% 以下（ ...

Group 1 - The core viewpoint of the article is the establishment of Bluefan Emergency Technology (Wuhan) Co., Ltd. as a new business entity aimed at expanding the domestic emergency rescue market in China [1] - The emergency rescue division of Bluefan Medical has developed a product portfolio that covers various fields and scenarios, including home, vehicle, public places, outdoor activities, travel, disaster relief, and pet care [1] - The company has completed most of the self-manufacturing and supply chain integration for its products, with the core product, the first aid kit, achieving an annual production capacity of 20 million sets [1]

最近三个交易日，28日-30日，蓝帆医疗分别获融资买入0.18亿元、0.13亿元、0.10亿元。 融券方面，当日融券卖出1.75万股，净卖出0.86万股。 来源：金融界 7月30日，沪深两融数据显示，蓝帆医疗获融资买入额0.10亿元，居两市第2304位，当日融资偿还额0.10 亿元，净买入59.01万元。 ...

Group 1 - The core viewpoint of the article is the establishment of a new company, 蓝帆应急科技(武汉)有限公司, by 蓝帆医疗 to expand its presence in the domestic emergency rescue market [1] - The new company will focus on various fields and scenarios including home, vehicle, public places, outdoor activities, travel, disaster relief, and pet care [1] - The emergency rescue division has completed most of its product manufacturing and supply chain integration, with a core product capacity of 20 million emergency kits per year [1]

Group 1 - The new round of drug procurement rules has been optimized to prevent excessive competition and ensure reasonable price reductions, with the lowest bidding companies required to justify their pricing [1][2] - The optimization of procurement rules reflects a systematic adjustment in high-value consumables procurement policies, moving away from the previous focus on low-price bidding [2] - The first round of coronary stent procurement significantly impacted the performance of winning companies, but the second round introduced a more moderate approach, allowing companies to bid below a set maximum price [2] Group 2 - Bluefan Medical, a leading company in cardiovascular high-value consumables, is expected to achieve better performance in its cardiovascular business due to the "anti-involution" policy changes [3] - The company reported a sales revenue exceeding 690 million yuan for the first half of 2025, representing a growth of over 20% compared to the same period last year, alongside a reduction in sales and management expense ratios [3] - Bluefan Medical has invested a total of 2 billion yuan in research and development from 2018 to 2024, leading to significant product approvals and market growth, including a 120% increase in sales of its innovative drug-coated balloon [4]

Core Viewpoint - The recent optimization of drug procurement rules in China aims to prevent excessive competition and ensure reasonable price reductions in the pharmaceutical industry, reflecting a shift towards a more sustainable market environment [1][2][3]. Group 1: Policy Changes - The new drug procurement rules will no longer solely rely on the lowest bid as the benchmark, requiring companies to justify their pricing and ensure it does not fall below cost [1]. - The optimization of procurement rules is seen as a necessary response to the negative impacts of excessive competition, particularly in high-value medical consumables [2][3]. - The shift in policy is part of a broader strategy to enhance procurement evaluation and promote standardized practices, indicating a consensus at the national level [3]. Group 2: Market Impact - Following the announcement, companies like Nanwei Medical and Anjisi, which were significantly affected by low-price competition, experienced positive stock performance [2]. - The changes in procurement policy are expected to create a more favorable competitive environment for companies, moving towards a "post-price reduction era" where quality development is emphasized [3]. Group 3: Company Performance - BluFan Medical, a key player in the cardiovascular high-value consumables sector, is anticipated to achieve better performance due to the "anti-involution" policy shift, with projected sales exceeding 690 million yuan in the first half of 2025, representing over 20% growth year-on-year [4]. - The company has built a comprehensive product matrix in the cardiovascular medical device field, which has allowed it to significantly increase its market share despite previous price pressures from procurement policies [4][6]. - With a cumulative R&D investment of 2 billion yuan from 2018 to 2024, BluFan Medical is positioned to benefit from recent innovations and policy support for high-quality drug and device development [5][6]. Group 4: Industry Outlook - The ongoing reforms in the medical industry are expected to accelerate recovery in the high-value consumables market, with BluFan Medical leading the narrative of valuation recovery and business growth [7]. - Other companies in the sector, such as Sanyou Medical and Nanwei Medical, are also experiencing improved market conditions due to the easing of procurement pressures and the introduction of new products [6][7].

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-061 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于董事会提议向下修正"蓝帆转债"转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、截至 2025 年 7 月 28 日，蓝帆医疗股份有限公司（以下简称"公司"）股价已 出现连续三十个交易日中至少有十五个交易日的收盘价低于当期转股价格 85%的情形， 已触发"蓝帆转债"转股价格向下修正条件。 2、经公司第六届董事会第二十六次会议审议通过，公司董事会提议向下修正 "蓝帆转债"转股价格。 3、本次向下修正"蓝帆转债"转股价格的提议尚需提交公司股东会审议。 一、可转债发行上市基本情况 （一）可转债发行情况 经中国证券监督管理委员会"证监许可〔2020〕710 号"文核准，公司于 2020 年 5 月 28 日公开发行了 3,144.04 万张可转换公司债券（以下简称"可转债"），每张面值 100 元，发 行总额314,404 万元 ...

证券代码：002382 证券简称：蓝帆医疗 公告编号：2025-062 债券代码：128108 债券简称：蓝帆转债 蓝帆医疗股份有限公司 关于召开 2025 年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 经蓝帆医疗股份有限公司（以下简称"公司"或"本公司"）第六届董事会第二十 六次会议审议通过，公司决定于2025年8月14日召开2025年第三次临时股东会，现将有 关事项通知如下： 一、召开会议基本情况 1、股东会届次：2025 年第三次临时股东会 2、股东会的召集人：公司第六届董事会 3、会议召开的合法、合规性：本次召开股东会的议案经公司第六届董事会第二十 六次会议审议通过，符合有关法律法规、深圳证券交易所业务规则和《蓝帆医疗股份有 限公司章程》的规定。 4、会议召开的日期、时间： （1）现场会议投票：股东本人出席现场会议或通过授权委托书委托他人出席现场 会议行使表决权。 （1）现场会议时间：2025 年 8 月 14 日（星期四）下午 14：00 （2）网络投票时间：2025 年 8 月 14 日 通过深圳证券交易所（以下简称"深 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-060 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 第六届董事会第二十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 起至本次修正可转债转股价格相关工作完成之日止。 本议案尚需提交股东会审议。 表决结果：同意票 8 票，反对票 0 票，弃权票 0 票。 具体内容详见刊登于公司指定的信息披露媒体《中国证券报》、《上海证券报》、《证 券时报》、《证券日报》和巨潮资讯网（http://www.cninfo.com.cn）上的《关于董事会提 议向下修正"蓝帆转债"转股价格的公告》。 2、审议并通过了《关于召开 2025 年第三次临时股东会的议案》。 同意公司于 2025 年 8 月 14 日召开 2025 年第三次临时股东会。 蓝帆医疗股份有限公司（以下简称"公司"）第六届董事会第二十六次会议于 2025 年 7 月 24 日以电子邮件的方式发出通知，于 2025 年 7 ...